Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chemocentryx Inc (CCXI)

Chemocentryx Inc (CCXI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,376,415
  • Shares Outstanding, K 61,645
  • Annual Sales, $ 36,130 K
  • Annual Income, $ -55,490 K
  • 60-Month Beta 2.28
  • Price/Sales 68.10
  • Price/Cash Flow N/A
  • Price/Book 35.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.30
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.32
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -30.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.72 +22.01%
on 03/18/20
51.01 -26.52%
on 03/05/20
-7.27 (-16.25%)
since 02/28/20
3-Month
30.72 +22.01%
on 03/18/20
51.36 -27.02%
on 02/19/20
+1.25 (+3.45%)
since 12/27/19
52-Week
6.16 +508.44%
on 08/06/19
51.36 -27.02%
on 02/19/20
+23.59 (+169.83%)
since 03/29/19

Most Recent Stories

More News
Why ChemoCentryx (CCXI) Stock Might be a Great Pick

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

CCXI : 37.53 (-2.65%)
ChemoCentryx (CCXI) Reports Q4 Loss, Tops Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CCXI : 37.53 (-2.65%)
ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4;

CCXI : 37.53 (-2.65%)
ChemoCentryx, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 10, 2020 / ChemoCentryx, Inc. (NASDAQ:CCXI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 5:00 PM...

CCXI : 37.53 (-2.65%)
CannTrust (CTST) to Report Q4 Earnings: What's in Store?

During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.

AVEO : 3.62 (-15.42%)
CCXI : 37.53 (-2.65%)
CTST : 0.6379 (-9.13%)
HARP : 11.59 (+1.22%)
ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released after market close on Tuesday, March 10, 2020. ChemoCentryx executive...

CCXI : 37.53 (-2.65%)
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CCXI : 37.53 (-2.65%)
What's in Store for Axsome (AXSM) This Earnings Season?

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

AVEO : 3.62 (-15.42%)
CCXI : 37.53 (-2.65%)
AXSM : 58.29 (-7.87%)
HARP : 11.59 (+1.22%)
What Lies Ahead for Cassava Sciences (SAVA) in Q4 Earnings?

During the Q4 investors' call, Cassava Sciences (SAVA) is likely to provide an update on its lead candidate PT-125, which is being developed for the treatment of Alzheimer's disease.

AVEO : 3.62 (-15.42%)
CCXI : 37.53 (-2.65%)
SAVA : 3.81 (-10.56%)
HARP : 11.59 (+1.22%)
Onconova (ONTX) to Report Q4 Earnings: What's in Store?

Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.

AVEO : 3.62 (-15.42%)
CCXI : 37.53 (-2.65%)
ONTX : 0.3039 (-5.00%)
HARP : 11.59 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CCXI with:

Business Summary

ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.

See More

Key Turning Points

2nd Resistance Point 41.09
1st Resistance Point 39.82
Last Price 37.61
1st Support Level 37.64
2nd Support Level 36.73

See More

52-Week High 51.36
Last Price 37.61
Fibonacci 61.8% 34.09
Fibonacci 50% 28.76
Fibonacci 38.2% 23.43
52-Week Low 6.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar